Drug intelligence / Profile preview

NeuroLeukin

Development stage: Preclinical
Lead developer: Therapeutic Solutions International
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intranasal

Overview

**NeuroLeukin** is a preclinical intranasal combination product from Campbell Neurosciences for depression and suicide risk. It combines autologous platelet-rich plasma with NanoStilbene, a patented pterostilbene delivery system, and is intended to increase brain-derived neurotrophic factor-mediated neurotrophic signaling. The proposed regimen is once-daily intranasal administration for one week.

Other names: NeuroLeukin

Targets

BDNF (Brain-derived neurotrophic factor)

Beyond the preview

Go deeper on NeuroLeukin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroLeukin.

Explore the full profile